of the 8th ESC Congress Edinburgh
2004
Copyright
2004 Taylor & Francis Limited. All rights reserved
STATE OF THE ART | FREE
COMMUNICATIONS |
POSTERS |
KEYNOTE SESSIONS | WORKSHOPS | SPONSORED
SYMPOSIA |
Symposium
1: New trends in European contraception (Schering) |
||
Contraceptive
use in European women: a research survey on contemporary behaviour |
S. Skouby
(Denmark) |
Abstract |
Long-term
contraception in young women: special focus on nulliparous women and contraception following abortion |
A. Gebbie (UK) | Abstract |
Contraception
as a therapeutic option in the treatment of menorrhagia |
H. Critchley
(UK) |
Abstract |
The
non-contraceptive benefits and acceptability of Yasmin® |
D. Mansour(UK) | Abstract |
Yasmin®
and the extended cycle regimen: current experience |
M. Sillem (Germany) | Abstract |
Symposium
2: The Vagina Dialogue: NuvaRing® and the benefits of vaginal administration (Organon) |
||
Women and their
vaginas |
G. Liekens (Belgium) | no abstract |
The clinical
profile of NuvaRing, update on new results |
S. Killick (UK) | no abstract |
NuvaRing and
the beauty of vaginal administration |
R. Arias (United
States) |
no abstract |
Symposium
3: Customizing care… The art and science of low dose OC prescribing (WyethPharmaceuticals) |
||
Oral contraceptive side effects: impact of estrogen
dose when selecting an oral contraceptive |
P. Darney | Abstract |
Acceptability, safety and premenstrual
symptomatology in women using an oral contraceptive containing gestodene 60mcg/ethinylestradiol 15mcg |
I. Barbosa | Abstract |
Symposium
4: Estrogen-freecontraception: the evolution of depot medroxyprogesterone acetate (Pfizer) |
||
Hormonal
contraception without estrogen: nondaily options |
A. Glasier (UK) | no abstract |
Expanding
low-dose options in contraception |
C. Brucker (Germany) | no abstract |
Maximizing
contraceptive convenience: managing expectations |
I. Milsom (Sweden) | no abstract |
Symposium
5: Contraception: why change? (Janssen-Cilag) |
||
Contraception: are we keeping up? | M.
O’Flynn (Rep. of Ireland) |
no abstract |
The transdermal route: what is it
delivering? |
C. Keck (Germany) | no abstract |
Where do we go from here? | J. Guillebaud (UK) | no abstract |